

Recommended Laboratory HIV Testing Algorithm for Serum or Plasma Specimens

- 1. Laboratories should conduct initial testing for HIV with an FDA-approved antigen/antibody combination immunoassay\* that detects HIV-1 and HIV-2 antibodies and HIV-1 p24 antigen to test for established HIV-1 or HIV-2 infection and for acute HIV-1 infection. No further testing is required for specimens that are nonreactive on the initial immunoassay.
- 2. Specimens with a reactive antigen/antibody combination immunoassay result (or repeatedly reactive, if repeat testing is recommended by the manufacturer or required by regulatory authorities) should be tested with an FDA-approved antibody immunoassay that differentiates HIV-1 antibodies from HIV-2 antibodies. Reactive results on the initial antigen/antibody combination immunoassay and the HIV-1/HIV-2 antibody differentiation immunoassay should be interpreted as positive for HIV-1 antibodies, HIV-2 antibodies, or HIV antibodies, undifferentiated.
- 3. Specimens that are reactive on the initial antigen/antibody combination immunoassay and nonreactive or indeterminate on the HIV-1/HIV-2 antibody differentiation immunoassay should be tested with an FDA-approved HIV-1 nucleic acid test (NAT).
  - A reactive HIV-1 NAT result and nonreactive HIV-1/HIV-2 antibody differentiation immunoassay result indicates laboratory evidence for acute HIV-1 infection.
  - A reactive HIV-1 NAT result and indeterminate HIV-1/HIV-2 antibody differentiation immunoassay result indicates the presence of HIV-1 infection confirmed by HIV-1 NAT.
  - A negative HIV-1 NAT result and nonreactive or indeterminate HIV-1/HIV-2 antibody differentiation immunoassay result indicates a false-positive result on the initial immunoassay.
- 4. Laboratories should use this same testing algorithm, beginning with an antigen/antibody combination immunoassay, with serum or plasma specimens submitted for testing after a reactive (preliminary positive) result from any rapid HIV test.

<sup>\*</sup> Exception: As of April 2014, data are insufficient to recommend use of the FDA-approved single-use rapid HIV-1/HIV-2 antigen/antibody combination immunoassay as the initial assay in the algorithm.

## Reporting results from the HIV diagnostic testing algorithm to persons ordering HIV tests and public health authorities

Test performed	Test results	Final interpretation for provider report	Test results to be reported to public health authorities
1. HIV-1/2 Ag/Ab combination immunoassay	1. Nonreactive	Negative for HIV-1 antigen and HIV-1/HIV-2 antibodies. No laboratory evidence of HIV infection. If acute HIV infection is suspected, consider testing for HIV-1 RNA.	Reporting this test result is not required.
<ol> <li>HIV-1/2 Ag/Ab combination immunoassay</li> <li>HIV-1/HIV-2 antibody differentiation immunoassay</li> </ol>	1. Reactive 2. HIV-1 reactive and HIV-2 nonreactive	Positive for HIV-1 antibodies. Laboratory evidence consistent with established HIV-1 infection is present.	Report test results 1 and 2.
1. HIV-1/2 Ag/Ab combo immunoassay 2. HIV-1/HIV-2 antibody differentiation immunoassay	1. Reactive 2. HIV-1 nonreactive and HIV-2 reactive	Positive for HIV-2 antibodies. Laboratory evidence of HIV-2 infection is present.	Report test results 1 and 2.
<ol> <li>HIV-1/2 Ag/Ab combination immunoassay</li> <li>HIV-1/HIV-2 antibody differentiation immunoassay</li> <li>HIV-1 RNA assay</li> </ol>	<ol> <li>Reactive</li> <li>Nonreactive or indeterminate</li> <li>RNA not detected</li> </ol>	HIV antibodies were not confirmed and HIV-1 RNA was not detected. No laboratory evidence of HIV-1 infection. Follow-up testing for HIV-2 should be performed if clinically indicated.	Reporting this test result is not required.
<ol> <li>HIV-1/2 Ag/Ab combination immunoassay</li> <li>HIV-1/HIV-2 antibody differentiation immunoassay</li> <li>HIV-1 RNA assay</li> </ol>	1. Reactive 2. Nonreactive 3. RNA detected	Positive for HIV-1. Laboratory evidence consistent with acute HIV-1 infection is present.	Report test results 1, 2, and 3.
<ol> <li>HIV-1/2 Ag/Ab combination immunoassay</li> <li>HIV-1/HIV-2 antibody differentiation immunoassay</li> <li>HIV-1 RNA assay</li> </ol>	<ol> <li>Reactive</li> <li>Indeterminate</li> <li>RNA detected</li> </ol>	Positive for HIV-1 antibodies. Laboratory evidence of HIV-1 infection confirmed by HIV-1 RNA.	Report test results 1, 2, and 3.
<ol> <li>HIV-1/2 Ag/Ab combination immunoassay</li> <li>HIV-1/HIV-2 antibody differentiation immunoassay</li> </ol>	1. Reactive 2. HIV-1 and HIV-2 reactive	Positive for HIV antibodies. Laboratory evidence of HIV infection is present. HIV antibodies could not be differentiated as HIV-1 or HIV-2. Additional testing for HIV-1 RNA or HIV-2 RNA should be performed if clinically indicated.	Report test results 1 and 2.
<ol> <li>HIV-1/2 Ag/Ab combination immunoassay</li> <li>HIV-1/HIV-2 antibody differentiation immunoassay</li> </ol>	<ol> <li>Reactive</li> <li>Nonreactive or indeterminate</li> </ol>	HIV-1 antibodies were not confirmed and HIV-1 RNA testing was not performed. Testing of this specimen is incomplete. Follow-up testing for HIV antibodies and HIV-1 RNA is recommended as soon as possible.	Report test results 1 and 2.

Abbreviations: Ag/Ab, antigen/antibody; RNA, ribonucleic acid.

Adapted from Interim Guidelines for Laboratories on the Use of a New Diagnostic Testing Algorithm for Human Immunodeficiency Virus (HIV) Infection. New York State Department of Health (http://www.health.ny.gov/diseases/aids/providers/regulations/testing/docs/guidelines\_diagnostic\_testing.pdf).